keyword
https://read.qxmd.com/read/38521284/emerge-of-colorectal-cancer-in-lynch-syndrome-despite-colonoscopy-surveillance-a-challenge-of-hide-and-seek
#21
REVIEW
Noah C Helderman, Monique E van Leerdam, Matthias Kloor, Aysel Ahadova, Maartje Nielsen
Even with colonoscopy surveillance, Lynch syndromes (LS) carriers still develop colorectal cancer (CRC). The cumulative incidence of CRCs under colonoscopy surveillance varies depending on the affected mismatch repair (MMR) gene. However, the precise mechanisms driving these epidemiological patterns remain incompletely understood. In recent years, several potential mechanisms explaining the occurrence of CRCs during colonoscopy surveillance have been proposed in individuals with and without LS. These encompass biological factors like concealed/accelerated carcinogenesis through a bypassed adenoma stage and accelerated progression from adenomas...
March 21, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38520006/targeting-inflammation-as-cancer-therapy
#22
REVIEW
Manni Wang, Siyuan Chen, Xuemei He, Yong Yuan, Xiawei Wei
Inflammation has accompanied human beings since the emergence of wounds and infections. In the past decades, numerous efforts have been undertaken to explore the potential role of inflammation in cancer, from tumor development, invasion, and metastasis to the resistance of tumors to treatment. Inflammation-targeted agents not only demonstrate the potential to suppress cancer development, but also to improve the efficacy of other therapeutic modalities. In this review, we describe the highly dynamic and complex inflammatory tumor microenvironment, with discussion on key inflammation mediators in cancer including inflammatory cells, inflammatory cytokines, and their downstream intracellular pathways...
March 22, 2024: Journal of Hematology & Oncology
https://read.qxmd.com/read/38515194/decoding-the-glycoproteome-a-new-frontier-for-biomarker-discovery-in-cancer
#23
REVIEW
Kai He, Maryam Baniasad, Hyunwoo Kwon, Tomislav Caval, Gege Xu, Carlito Lebrilla, Daniel W Hommes, Carolyn Bertozzi
Cancer early detection and treatment response prediction continue to pose significant challenges. Cancer liquid biopsies focusing on detecting circulating tumor cells (CTCs) and DNA (ctDNA) have shown enormous potential due to their non-invasive nature and the implications in precision cancer management. Recently, liquid biopsy has been further expanded to profile glycoproteins, which are the products of post-translational modifications of proteins and play key roles in both normal and pathological processes, including cancers...
March 22, 2024: Journal of Hematology & Oncology
https://read.qxmd.com/read/38485551/targeted-agents-in-esophagogastric-cancer-beyond-human-epidermal-growth-factor-receptor-2
#24
REVIEW
Eric Mehlhaff, Devon Miller, Johnathan E Ebben, Oleksii Dobrzhanskyi, Nataliya V Uboha
Gastroesophageal cancers are highly diverse tumors in terms of their anatomic and molecular characteristics, making drug development challenging. Recent advancements in understanding the molecular profiles of these cancers have led to the identification of several new biomarkers. Ongoing clinical trials are investigating new targeted agents with promising results. CLDN18.2 has emerged as a biomarker with established activity of associated targeted therapies. Other targeted agents, such as bemarituzumab and DKN-01, are under active investigation...
March 13, 2024: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/38484344/mortality-in-patients-with-hematological-malignancies-febrile-neutropenia-and-septic-shock
#25
JOURNAL ARTICLE
Beda Islas-Muñoz, Patricia Volkow-Fernández, Jorge Silva-Zamora, Ana Ramírez-Ibarguen, Patricia Cornejo-Juárez
INTRODUCTION: Patients with severe neutropenia who develop septic shock (SS) have high mortality. This study aimed to evaluate the risk factors and mortality of SS in patients with HM and febrile neutropenia. METHODOLOGY: We included all patients with hematological malignancies (HM) who presented fever and severe neutropenia, admitted to an oncological tertiary care center in Mexico City for one year. RESULTS: Two hundred ninety-two episodes of fever and severe neutropenia were documented; 68 patients (23...
February 29, 2024: Journal of Infection in Developing Countries
https://read.qxmd.com/read/38471620/car-t-treatment-beyond-cancer-hope-for-immunomodulatory-therapy-of-non-cancerous-diseases
#26
REVIEW
Zhibo Yang, Yingfeng Liu, Hai Zhao
Engineering a patient's own T cells to accurately identify and eliminate cancer cells has effectively cured individuals afflicted with previously incurable hematologic cancers. These findings have stimulated research into employing chimeric antigen receptor (CAR) T therapy across various areas within the field of oncology. However, evidence from both clinical and preclinical investigations emphasize the broader potential of CAR T therapy, extending beyond oncology to address autoimmune disorders, persistent infections, cardiac fibrosis, age-related ailments and other conditions...
March 10, 2024: Life Sciences
https://read.qxmd.com/read/38462151/killing-two-birds-with-one-stone-abscopal-effect-mechanism-and-its-application-prospect-in-radiotherapy
#27
REVIEW
Boyi Yu, Yuting Gao, Jiaxin Li, Feifei Gao, Jiahao Zhang, Linjing Li, Xianglong Feng, Dashan Zuo, Xiaodong Jin, Weiqiang Chen, Qiang Li
Abscopal effects are characterized by the emergence of neoplasms in regions unrelated to the primary radiation therapy site, displaying a gradual attenuation or regression throughout the progression of radiation therapy, which have been of interest to scientists since Mole's proposal in 1953. The incidence of abscopal effects in radiation therapy is intricately linked to the immune system, with both innate and adaptive immune responses playing crucial roles. Biological factors impacting abscopal effects ultimately exert their influence on the intricate workings of the immune system...
April 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38462150/cyclin-dependent-kinase-2-cdk2-inhibitors-and-others-novel-cdk-inhibitors-cdki-in-breast-cancer-clinical-trials-current-impact-and-future-directions
#28
REVIEW
Riccardo Gerosa, Rita De Sanctis, Flavia Jacobs, Chiara Benvenuti, Mariangela Gaudio, Giuseppe Saltalamacchia, Rosalba Torrisi, Giovanna Masci, Chiara Miggiano, Francesco Agustoni, Paolo Pedrazzoli, Armando Santoro, Alberto Zambelli
Aberrant cyclin-dependent kinase 2 (CDK2) activation has been identified as a main resistance mechanism to CDK4/6 inhibition in hormone-receptor positive (HR+) breast cancer. Additionally, consistent preclinical evidence states its crucial role in MYC and CCNE1 overexpressed cancer survival, such as triple-negative breast cancers (TNBC), thus representing an appealing and relatively unexplored target treatment opportunity. Despite emerging initial results of novel CDK2 inhibitors (CDK2i) activity, a comprehensive outcomes collection is currently absent from the scientific literature...
March 8, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38460928/microbiome-and-lung-cancer-carcinogenic-mechanisms-early-cancer-diagnosis-and-promising-microbial-therapies
#29
REVIEW
Weici Liu, Zheshun Pi, Xiaokun Wang, Chenwei Shang, Chenghu Song, Ruixin Wang, Zhao He, Xu Zhang, Yuan Wan, Wenjun Mao
Microbiomes in the lung, gut, and oral cavity are correlated with lung cancer initiation and progression. While correlations have been preliminarily established in earlier studies, delving into microbe-mediated carcinogenic mechanisms will extend our understanding from correlation to causation. Building upon the causative relationships between microbiome and lung cancer, a novel concept of microbial biomarkers has emerged, mainly encompassing cancer-specific bacteria and circulating microbiome DNA. They might function as noninvasive liquid biopsy techniques for lung cancer early detection...
March 7, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38456804/large-scale-pan-cancer-cell-line-screening-identifies-actionable-and-effective-drug-combinations
#30
JOURNAL ARTICLE
Azadeh C Bashi, Elizabeth A Coker, Krishna C Bulusu, Patricia Jaaks, Claire Crafter, Howard Lightfoot, Marta Milo, Katrina McCarten, David F Jenkins, Dieudonne van der Meer, James T Lynch, Syd Barthorpe, Courtney L Andersen, Simon T Barry, Alexandra Beck, Justin Cidado, Jacob A Gordon, Caitlin Hall, James Hall, Iman Mali, Tatiana Mironenko, Kevin Mongeon, James Morris, Laura Richardson, Paul D Smith, Omid Tavana, Charlotte Tolley, Frances Thomas, Brandon S Willis, Wanjuan Yang, Mark J O'Connor, Ultan McDermott, Susan E Critchlow, Lisa Drew, Stephen E Fawell, Jerome T Mettetal, Mathew J Garnett
UNLABELLED: Oncology drug combinations can improve therapeutic responses and increase treatment options for patients. The number of possible combinations is vast and responses can be context-specific. Systematic screens can identify clinically relevant, actionable combinations in defined patient subtypes. We present data for 109 anticancer drug combinations from AstraZeneca's oncology small molecule portfolio screened in 755 pan-cancer cell lines. Combinations were screened in a 7 × 7 concentration matrix, with more than 4 million measurements of sensitivity, producing an exceptionally data-rich resource...
March 8, 2024: Cancer Discovery
https://read.qxmd.com/read/38452788/oral-decitabine-and-cedazuridine-plus-venetoclax-for-older-or-unfit-patients-with-acute-myeloid-leukaemia-a-phase-2-study
#31
JOURNAL ARTICLE
Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, Yesid Alvarado, Alex Bataller, Tareq Abuasab, Rabiul Islam, Kathryn Montalbano, Ghayas Issa, Abhishek Maiti, Musa Yilmaz, Nitin Jain, Lucia Masarova, Steven Kornblau, Elias Jabbour, Guillermo Montalban-Bravo, Caitlin R Rausch, Sherry Pierce, Courtney D DiNardo, Tapan Kadia, Naval Daver, Marina Konopleva, Xuelin Huang, Hagop Kantarjian, Farhad Ravandi
BACKGROUND: Hypomethylating agents combined with venetoclax are effective regimens in patients with acute myeloid leukaemia who are ineligible for intensive chemotherapy. Decitabine and cedazuridine (ASTX727) is an oral formulation of decitabine that achieves equivalent area-under-curve exposure to intravenous decitabine. We performed a single centre phase 2 study to evaluate the efficacy and safety of ASTX727 plus venetoclax. METHODS: This study enrolled patients with newly diagnosed (frontline treatment group) acute myeloid leukaemia who were ineligible for intensive chemotherapy (aged ≥75 years, an Eastern Cooperative Oncology Group [ECOG] performance status of 2-3, or major comorbidities) or relapsed or refractory acute myeloid leukaemia...
April 2024: Lancet Haematology
https://read.qxmd.com/read/38447107/the-incidence-of-postoperative-complications-following-lumbar-and-bone-marrow-punctures-in-pediatric-anesthesia-insights-from-apricot
#32
JOURNAL ARTICLE
Krystelle Dagher, Claudia Benvenuti, Kathy Virag, Walid Habre
OBJECTIVE OF THE STUDY: Bone marrow aspiration and lumbar puncture are procedures frequently performed in pediatric oncology. We aimed at assessing the incidence and risk factors of perioperative complications in children undergoing these procedures under sedation or general anesthesia. METHODS: Based on the APRICOT study, we performed a secondary analysis, including 893 children undergoing bone marrow aspiration and lumbar puncture. The primary outcome was the incidence of perioperative complications...
March 4, 2024: Journal of Pediatric Hematology/oncology
https://read.qxmd.com/read/38446370/acetaminophen-overdose-analysis-of-2018-us-nationwide-emergency-database
#33
JOURNAL ARTICLE
Faria Sami, Sarah Berg, Augustine M Manadan, Mark B Mycyk
INTRODUCTION: Recognized risk factors for acetaminophen overdose include alcohol, opioids, and mood disorders. The aim of this study is to assess additional risk factors for acetaminophen overdose evaluated in the emergency department (ED). METHODS: A retrospective study was performed using the 2018 US Nationwide Emergency Department Sample (NEDS). All adult ED visits for acetaminophen overdose were included in the study group and those without it were taken as control...
March 6, 2024: Internal and Emergency Medicine
https://read.qxmd.com/read/38431241/mapping-the-research-landscape-of-hpv-positive-oropharyngeal-cancer-a-bibliometric-analysis
#34
REVIEW
Angela Ammirabile, Federico Mastroleo, Giulia Marvaso, Daniela Alterio, Ciro Franzese, Marta Scorsetti, Pierfrancesco Franco, Caterina Giannitto, Barbara Alicja Jereczek-Fossa
OBJECTIVE: The aim of the study is to evaluate the scientific interest, the collaboration patterns and the emerging trends regarding HPV+ OPSCC diagnosis and treatment. MATERIALS AND METHODS: A cross-sectional bibliometric analysis of articles reporting on HPV+ OPSCC within Scopus database was performed and all documents published up to December 31th, 2022 were eligible for analysis. Outcomes included the exploration of key characteristics (number of manuscripts published per year, growth rate, top productive countries, most highly cited papers, and the most well-represented journals), collaboration parameters (international collaboration ratio and networks, co-occurrence networks), keywords analysis (trend topics, factorial analysis)...
March 1, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38429828/drug-conjugates-for-the-treatment-of-lung-cancer-from-drug-discovery-to-clinical-practice
#35
REVIEW
Ling Zhou, Yunlong Lu, Wei Liu, Shanglong Wang, Lingling Wang, Pengdou Zheng, Guisha Zi, Huiguo Liu, Wukun Liu, Shuang Wei
A drug conjugate consists of a cytotoxic drug bound via a linker to a targeted ligand, allowing the targeted delivery of the drug to one or more tumor sites. This approach simultaneously reduces drug toxicity and increases efficacy, with a powerful combination of efficient killing and precise targeting. Antibody‒drug conjugates (ADCs) are the best-known type of drug conjugate, combining the specificity of antibodies with the cytotoxicity of chemotherapeutic drugs to reduce adverse reactions by preferentially targeting the payload to the tumor...
March 1, 2024: Experimental Hematology & Oncology
https://read.qxmd.com/read/38425652/anticancer-therapy-induced-adverse-drug-reactions-in-children-and-preventive-and-control-measures
#36
REVIEW
Hui Yan, Penggao Wang, Fang Yang, Weyland Cheng, Congcong Chen, Bo Zhai, Yang Zhou
In recent years, considerable achievements have been made in pediatric oncology with the innovation and development of antitumor drugs. However, compared to adults, children as a special group have not yet matured fully in terms of liver and kidney function. Moreover, pediatric patients are prone to more adverse drug reactions (ADRs) from the accumulation of antineoplastic drugs due to their smaller body size and larger body surface area. Chemotherapy-related ADRs have become a non-negligible factor that affects cancer remission...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38423658/immunotherapy-combined-with-standard-therapies-in-head-and-neck-squamous-cell-carcinoma-a-meta-analysis
#37
REVIEW
Daisy Eden, Aruni Ghose, Michele Moschetta, José Alejandro Pérez-Fidalgo, Elie Rassy, Stergios Boussios
Head and neck squamous cell carcinoma (HNSCC) is a deadly disease with a poor prognosis due to late diagnosis and limited treatment options. Immunotherapy (IT) is emerging as a promising approach, especially after the failure of standard of care therapies (STs). The objective of this systematic review and meta-analysis was to evaluate whether the addition of IT to STs improves outcomes for patients with HNSCC, including overall survival (OS), progression-free survival (PFS), and quality of life (QoL). This review employed the Population Intervention Comparison and Outcome (PICO) framework to identify relevant search terms in electronic databases, and also included supplementary hand searches...
March 2024: Anticancer Research
https://read.qxmd.com/read/38423630/comparative-efficacy-and-safety-of-standard-and-biweekly-trifluridine-tipiracil-regimen-in-patients-with-colorectal-cancer
#38
JOURNAL ARTICLE
Shinsuke Hara, Daisuke Sakai, Kenji Ikemura, Takuya Shintani, Tomoya Yamamoto, Taroh Satoh, Masahiro Okuda
BACKGROUND/AIM: Trifluridine/tipiracil (FTD/TPI) is used to treat metastatic colorectal cancer (mCRC). Since the standard regimen of FTD/TPI features a complex dosing schedule and frequently results in severe hematological toxicities, a simplified regimen has emerged, in which FTD/TPI is orally administered biweekly. However, the survival benefits and potential adverse events associated with the biweekly FTD/TPI regimen have not been fully evaluated in previous reports. Therefore, in this study, the differences in efficacy and safety between the standard and biweekly FTD/TPI regimens were retrospectively investigated in patients with mCRC...
March 2024: Anticancer Research
https://read.qxmd.com/read/38408159/pediatric-plexiform-fibromyxoma-a-case-report
#39
JOURNAL ARTICLE
Patricia Bugeda Gómez, Adrià Costa-Roig, Carolina Montecino Romanini, Ignacio Miró Rubio, Santiago Guindos Rúa, Diana C Lara Cárdenas, Micaela Germani, María Roca Roca, Cleofe Romagosa Pérez Portabella, Marta Garrido Pontnou, Javier Hernández Losa, Luis F Sanchís Solera
The plexiform fibromyxoma is a rare mesenchymal tumor in adults that generally originates in the antrum of stomach, being its occurrence in pediatric patients exceptional. It was classified as a distinct entity by World Health Organization in 2010. No recurrences and metastases have been documented in many of the reported patients to date, being the surgical treatment curative. We report the case of a 3-month-old infant who presented to the emergency department with an episode of intestinal subocclusion requiring an emergent surgery...
February 26, 2024: Journal of Pediatric Hematology/oncology
https://read.qxmd.com/read/38402237/ffar2-expressing-myeloid-derived-suppressor-cells-drive-cancer-immunoevasion
#40
JOURNAL ARTICLE
Zeda Zhao, Juliang Qin, Ying Qian, Chenshen Huang, Xiaohong Liu, Ning Wang, Liqin Li, Yuqing Chao, Binghe Tan, Na Zhang, Min Qian, Dali Li, Mingyao Liu, Bing Du
BACKGROUND: Emerging evidences suggest that aberrant metabolites contributes to the immunosuppressive microenvironment that leads to cancer immune evasion. Among tumor immunosuppressive cells, myeloid-derived suppressor cells (MDSCs) are pathologically activated and extremely immunosuppressive, which are closely associated with poor clinical outcomes of cancer patients. However, the correlation between MDSCs mediated immunosuppression and particular cancer metabolism remained elusive...
February 24, 2024: Journal of Hematology & Oncology
keyword
keyword
79243
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.